JPMorgan Chase & Co. Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price

Zoetis (NYSE:ZTS) had its price objective reduced by equities researchers at JPMorgan Chase & Co. from $130.00 to $115.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 58.26% from the company’s previous close.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. TD Cowen lowered their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. William Blair restated a “market perform” rating on shares of Zoetis in a research note on Thursday. Finally, Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Seven equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $115.92.

Zoetis Stock Down 6.0%

Shares of NYSE:ZTS traded down $4.60 during mid-day trading on Friday, reaching $72.67. 7,805,101 shares of the stock were exchanged, compared to its average volume of 5,760,366. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The company has a market cap of $30.46 billion, a P/E ratio of 12.03, a P/E/G ratio of 1.16 and a beta of 0.74. Zoetis has a one year low of $71.47 and a one year high of $160.48. The stock’s 50 day simple moving average is $76.76 and its 200-day simple moving average is $100.95.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the previous year, the business posted $1.76 EPS. The business’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts predict that Zoetis will post 6.87 EPS for the current year.

Insiders Place Their Bets

In other news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zoetis

Hedge funds and other institutional investors have recently bought and sold shares of the business. J. Stern & Co. LLP raised its stake in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. Norges Bank bought a new position in Zoetis during the fourth quarter worth $734,425,000. Vanguard Group Inc. increased its holdings in shares of Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. BlackRock Inc. raised its position in shares of Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. Finally, Ruane Cunniff & Goldfarb L.P. bought a new position in shares of Zoetis in the first quarter valued at about $286,660,000. Institutional investors own 92.80% of the company’s stock.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Q2 earnings beat estimates: Zoetis reported adjusted earnings of $1.87 per share, ahead of the approximately $1.85 consensus and up from $1.76 a year earlier. However, revenue of $2.47 billion slightly missed expectations and was essentially flat year over year. Zoetis Surpasses Q2 Earnings Estimates
• Neutral Sentiment: Finance leadership change: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with reports also describing an expanded chief operating officer role. The change could support execution, but it is unlikely to offset the near-term demand concerns. Zoetis Appoints Jay Saccaro
• Negative Sentiment: 2026 guidance was cut materially: Zoetis now expects adjusted earnings per share of $6.15-$6.25, below the roughly $6.87 analyst consensus, and revenue of $9.1-$9.3 billion versus estimates near $9.8 billion. The reduced forecast signals that management expects softer growth and lower profitability for the year. Zoetis Q2 Earnings Beat, Revenue Miss, 2026 View Cut
• Negative Sentiment: Companion Animal weakness deepened: Management cited lower veterinary traffic, greater customer price sensitivity and increased competition. Zoetis plans additional promotions to defend market share, which may pressure pricing and margins. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.